CA2579119C — Crystalline forms of the mono-sodium salt of d-isoglutamyl-d-tryptophan
Assigned to Apotex Technologies Inc · Expires 2013-03-05 · 13y expired
What this patent protects
The present invention relates to crystalline forms of the mono-sodium salt of D--isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present i…
USPTO Abstract
The present invention relates to crystalline forms of the mono-sodium salt of D--isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 1 (polymorphic form F), the crystal modification 2 (polymorphic form I), and the crystal modification (polymorphic form X) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.